Statin use in patients with peripheral arterial disease

Journal of Vascular Surgery

Volumn 64, Issue 6, 2016, Pages 1881-1888

  Harris, Sheena K ^a   Roos, Matt G ^a   Landry, Gregory J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID PLUS SIMVASTATIN; PLACEBO; SIMVASTATIN;

AMNESIA; ANALGESIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONFUSION; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DRUG EFFECT; DRUG WITHDRAWAL; ENDOVASCULAR SURGERY; EVIDENCE BASED PRACTICE; HEART DISEASE; HUMAN; LIMB AMPUTATION; LIVER INJURY; META ANALYSIS (TOPIC); MUSCLE WEAKNESS; MYALGIA; MYOPATHY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; POSTOPERATIVE COMPLICATION; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TIME TO TREATMENT; WALKING; ADVERSE EFFECTS; AMPUTATION; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; LIMB SALVAGE; MORTALITY; PERIPHERAL ARTERIAL DISEASE; PROTECTION; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AMPUTATION; DISEASE-FREE SURVIVAL; ENDOVASCULAR PROCEDURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIMB SALVAGE; PERIPHERAL ARTERIAL DISEASE; PROTECTIVE FACTORS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84996526132     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2016.08.094     Document Type: Article

References (46)

1. 1 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
2. 2 Fleisher, L.A., Fleischmann, K.E., Auerbach, A.D., Barnason, S.A., Beckman, J.A., Bozkurt, B., et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American College of Surgeons, American Society of Anesthesiologists, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Vascular Medicine Endorsed by the Society of Hospital Medicine. J Nucl Cardiol 22 (2015), 162–215.
3. 3 Law, M.R., Wald, N.J., Rudnicka, A.R., Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 326, 2003, 1423.
4. 4 Ridker, P.M., Danielson, E., Fonseca, F.A.H., Genest, J., Gotto, A.M., Kastelein, J.J.P., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
5. 5 Libby, P., Aikawa, M., Mechanisms of plaque stabilization with statins. Am J Cardiol 91 (2003), 4B–8B.
6. 6 Yang, Z., Kozai, T., van de Loo, B., Viswambharan, H., Lachat, M., Turina, M.I., et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 36 (2000), 1691–1697.
7. 7 Miyauchi, K., Kasai, T., Yokayama, T., Aihara, K., Kurata, T., Kajimoto, K., et al. Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circ J 72 (2008), 832–838.
8. 8 Yokoyama, T., Miyauchi, K., Kurata, T., Satoh, H., Daida, H., Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis 174 (2004), 253–259.
9. 9 Rikitake, Y., Liao, J.K., Rho GTPases, statins, and nitric oxide. Circ Res 97 (2005), 1232–1235.
10. 10 Group OLoEW. The Oxford Levels of Evidence 2. 2011, Oxford Centre for Evidence-Based Medicine, Oxford, UK.
11. 11 Aung, P.P., Maxwell, H.G., Jepson, R.G., Price, J.F., Leng, G.C., Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev(4), 2007, CD000123.
12. 12 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
13. 13 Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45 (2007), 645–654 discussion: 653-4.
14. 14 Mohler, E.R. 3rd, Hiatt, W.R., Creager, M.A., Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003), 1481–1486.
15. 15 Antoniou, G.A., Fisher, R.K., Georgiadis, G.S., Antoniou, S.A., Torella, F., Statin therapy in lower limb peripheral arterial disease: systematic review and meta-analysis. Vasc Pharmacol 63 (2014), 79–87.
16. 16 De Martino, R.R., Beck, A.W., Hoel, A.W., Hallett, J.W., Arya, S., Upchurch, G.R. Jr., et al. Preoperative antiplatelet and statin treatment was not associated with reduced myocardial infarction after high-risk vascular operations in the Vascular Quality Initiative. J Vasc Surg 63 (2016), 182–189.e2.
17. 17 Ramos, R., Garcia-Gil, M., Comas-Cufi, M., Quesada, M., Marrugat, J., Elosua, R., et al. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. J Am Coll Cardiol 67 (2016), 630–640.
18. 18 Schanzer, A., Hevelone, N., Owens, C.D., Beckman, J.A., Belkin, M., Conte, M.S., Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 47 (2008), 774–781.e1.
19. 19 Suckow, B.D., Kraiss, L.W., Schanzer, A., Stone, D.H., Kalish, J., DeMartino, R.R., et al. Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survival. J Vasc Surg 61 (2015), 126–133.e1.
20. 20 Mondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T., Agricola, E., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 (2003), 359–364.
21. 21 Aronow, W.S., Nayak, D., Woodworth, S., Ahn, C., Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 92 (2003), 711–712.
22. 22 Brunner, G., Yang, E.Y., Kumar, A., Sun, W., Virani, S.S., Negi, S.I., et al. The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis 231 (2013), 371–377.
23. 23 Weintraub, W.S., Boccuzzi, S.J., Klein, J.L., Kosinski, A.S., King, S.B. 3rd, Ivanhoe, R., et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 331 (1994), 1331–1337.
24. 24 Birch, N., Fillaus, J., Florescu, M.C., The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses. Hemodial Int 17 (2013), 586–593.
25. 25 Walter, D.H., Schachinger, V., Elsner, M., Mach, S., Auch-Schwelk, W., Zeiher, A.M., Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 85 (2000), 962–968.
26. 26 Iakovou, I., Schmidt, T., Bonizzoni, E., Ge, L., Sangiorgi, G.M., Stankovic, G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005), 2126–2130.
27. 27 Zago, A.C., Matte, B.S., Reginato, L., Iturry-Yamamoto, G., Krepsky, A., Bergoli, L.C., et al. First-in-man study of simvastatin-eluting stent in de novo coronary lesions: the SIMVASTENT study. Circ J 76 (2012), 1109–1114.
28. 28 Siracuse, J.J., Giles, K.A., Pomposelli, F.B., Hamdan, A.D., Wyers, M.C., Chaikof, E.L., et al. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. J Vasc Surg 55 (2012), 1001–1007.
29. 29 Silva, M.A., Swanson, A.C., Gandhi, P.J., Tataronis, G.R., Statin-related adverse events: a meta-analysis. Clin Ther 28 (2006), 26–35.
30. 30 Silva, M., Matthews, M.L., Jarvis, C., Nolan, N.M., Belliveau, P., Malloy, M., et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 29 (2007), 253–260.
31. 31 Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
32. 32 Pedersen, T.R., Cater, N.B., Faergeman, O., Kastelein, J.J., Olsson, A.G., Tikkanen, M.J., et al. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiol 106 (2010), 354–359.
33. 33 Stock, J., Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group. Atherosclerosis 242 (2015), 346–350.
34. 34 Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R.G., Laaksonen, R., et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 96 (2014), 470–476.
35. 35 Gillett, R.C. Jr., Norrell, A., Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician 83 (2011), 711–716.
36. 36 Chang, C.H., Chang, Y.C., Lee, Y.C., Liu, Y.C., Chuang, L.M., Lin, J.W., Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study. J Gastroenterol Hepatol 30 (2015), 155–162.
37. 37 Kumbhani, D.J., Steg, P.G., Cannon, C.P., Eagle, K.A., Smith, S.C. Jr., Goto, S., et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 35 (2014), 2864–2872.
38. 38 Vidula, H., Tian, L., Liu, K., Criqui, M.H., Ferrucci, L., Guralnik, J.M., et al. Comparison of Effects of Statin Use on Mortality in Patients With Peripheral Arterial Disease With Versus Without Elevated C-Reactive Protein and D-Dimer Levels. Am J Cardiol 105 (2010), 1348–1352.
39. 39 Schillinger, M., Exner, M., Mlekusch, W., Amighi, J., Sabeti, S., Muellner, M., et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 25 (2004), 742–748.
40. 40 Westin, G.G., Armstrong, E.J., Bang, H., Bang, H., Yeo, K.K., Anderson, D., et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 63 (2014), 682–690.
41. 41 Baril, D.T., Patel, V.I., Judelson, D.R., Goodney, P.P., McPhee, J.T., Hevelone, N.D., et al. Outcomes of lower extremity bypass performed for acute limb ischemia. J Vasc Surg 58 (2013), 949–956.
42. 42 Tomoi, Y., Soga, Y., Iida, O., Hirano, K., Suzuki, K., Kawasaki, D., et al. Efficacy of statin treatment after endovascular therapy for isolated below-the-knee disease in patients with critical limb ischemia. Cardiovasc Interv Ther 28 (2013), 374–382.
43. 43 Aiello, F.A., Khan, A.A., Meltzer, A.J., Gallagher, K.A., McKinsey, J.F., Schneider, D.B., Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J Vasc Surg 55 (2012), 371–380.
44. 44 Ward, R.P., Leeper, N.J., Kirkpatrick, J.N., Lang, R.M., Sorrentino, M.J., Williams, K.A., The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 104 (2005), 264–268.
45. 45 Henke, P.K., Blackburn, S., Proctor, M.C., Stevens, J., Mukherjee, D., Rajagopalin, S., et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 39 (2004), 357–365.
46. 46 Abbruzzese, T.A., Havens, J., Belkin, M., Donaldson, M.C., Whittemore, A.D., Liao, J.K., et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 39 (2004), 1178–1185.